KSP37 Inhibitors
KSP37 Inhibitors are compounds that can modulate the activity of the protein KSP37, either directly or more likely, indirectly. The indirect inhibition strategy targets signaling pathways that KSP37 may be associated with. For example, inhibitors such as SB203580, SP600125, or U0126 can indirectly influence its function. Likewise, the PI3K pathway is critical in a variety of cellular processes, and compounds like LY294002 and Wortmannin, which target this pathway, may exert effects on KSP37.
Other potential influencing pathways include mTOR, JAK-STAT, and NF-κB, with Rapamycin, AG490, and BAY 11-7082 respectively serving as potential inhibitors. Furthermore, broad-spectrum inhibitors like Staurosporine can play a role in multiple pathways and, by extension, proteins associated or modulated by these pathways. The chosen chemicals represent a strategic approach to indirectly modulate KSP37 through these pathways. By targeting the mentioned pathways, these compounds can indirectly influence the function, stability, or interactions of KSP37 within the cellular environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
If KSP37 interacts with the MAPK pathway, SB203580 can be an indirect inhibitor by inhibiting p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
If the JNK pathway influences KSP37, SP600125 can act as an indirect inhibitor by targeting JNK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
By inhibiting PI3K, LY294002 can potentially modulate proteins associated with the PI3K pathway, including KSP37 if linked. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Another MEK inhibitor affecting the MEK/ERK pathway and possibly influencing KSP37 if interconnected. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
If KSP37's function is linked to the PI3K pathway, Wortmannin can indirectly modulate it by inhibiting PI3K. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By targeting mTOR, Rapamycin can influence proteins related to mTOR signaling, potentially including KSP37. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG490 inhibits the JAK-STAT pathway. If KSP37 is interconnected with this pathway, AG490 can serve as an indirect inhibitor. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
If KSP37's activity is linked to the NF-κB pathway, BAY 11-7082 can act as an indirect inhibitor by targeting NF-κB. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This broad-spectrum kinase inhibitor can modulate multiple pathways, possibly including those influencing KSP37. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
By inhibiting PKC, GF109203X can modulate proteins involved with the PKC pathway, potentially affecting KSP37 if related. | ||||||